#### 1 NGLY1 Deficiency: A Prospective Natural History Study (NHS)

- 2 Sandra Tong<sup>2</sup>, Pamela Ventola<sup>3,4</sup>, Christina H. Frater<sup>1</sup>, Jenna Klotz<sup>1</sup>, Jennifer M. Phillips<sup>1</sup>,
- 3 Srikanth Muppidi<sup>1</sup>, Selina S. Dwight<sup>2</sup>, William F. Mueller<sup>2</sup>, Brendan J. Beahm<sup>2</sup>, Matt Wilsey<sup>2</sup>,
- 4 Kevin J. Lee<sup>2</sup>
- <sup>1</sup>Department of Neurology, Stanford University, Stanford, CA, USA 94305
- <sup>6</sup> <sup>2</sup>Grace Science Foundation, Menlo Park, CA, 94305
- <sup>3</sup>Cogstate, New Haven, CT, 06510
- <sup>8</sup> <sup>4</sup>Yale Child Study Ctr, New Haven, CT, 06519
- 9 \*Corresponding Author: <u>kevin@gracescience.org;</u> 646-847-8533
- 10

#### 11 Abstract

12 N-glycanase 1 (NGLY1) Deficiency is a debilitating, ultra-rare autosomal recessive disorder 13 caused by loss of function of NGLY1, a cytosolic enzyme that deglycosylates other proteins. It is 14 characterized by severe global developmental delay and/or intellectual disability, hyperkinetic 15 movement disorder, transient elevation of transaminases, (hypo)alacrima, and progressive, 16 diffuse, length-dependent sensorimotor polyneuropathy. A prospective natural history study 17 (NHS) was conducted to elucidate clinical features and disease course. Twenty-nine participants 18 were enrolled (15 onsite, 14 remotely) and followed for up to 32 months, representing  $\sim 29\%$  of 19 the  $\sim 100$  patients identified worldwide. Participants exhibited profound developmental delays,

20 with almost all developmental quotients below 20 on the Mullen Scales of Early Learning, well 21 below the normative score of 100. Increased difficulties with sitting and standing suggested 22 decline in motor function over time. Most patients presented with (hypo)alacrima and reduced 23 sweat response. Pediatric quality of life was poor except for emotional function. 24 Language/communication and motor skill problems including hand use were reported by 25 caregivers as the most bothersome symptoms. Levels of the substrate biomarker, GlcNAc-Asn 26 (aspartylglucosamine; GNA), were consistently elevated in all participants over time, 27 independent of age. Liver enzymes were elevated for some participants but improved especially 28 in younger patients and did not reach levels indicating severe liver disease. Three participants 29 died during the study period. Data from this NHS informs selection of endpoints and assessments 30 for future clinical trials for NGLY1 Deficiency interventions. Potential endpoints include GNA 31 biomarker levels, neurocognitive assessments, autonomic and motor function (particularly hand 32 use), (hypo)alacrima, and quality of life.

# 33 Introduction

34	<i>N</i> -glycanase 1 (NGLY1) Deficiency (OMIM $\underline{615273}$ ) is a severely debilitating, ultra-rare,
35	autosomal recessive neurodevelopmental disorder characterized by five core clinical features:
36	global developmental delay and/or intellectual disability, a hyperkinetic movement disorder,
37	transient elevation of transaminases, (hypo)alacrima, and a progressive, diffuse, length-
38	dependent sensorimotor polyneuropathy (Adams 2018; Enns 2014; Lam 2018). In addition to
39	these five core features, individuals may experience seizures, reduced ability to sweat, skeletal
40	problems such as contractures, scoliosis, and skeletal deformities, hearing loss, vision
41	impairment, and adrenal insufficiency (Lam 2018). There are approximately 100 individuals
42	living with NGLY1 Deficiency identified globally (Pandey 2022). Because so few cases have
43	been identified, estimated lifespan is unknown. While some individuals survive into early
44	adulthood, there have been reports of death during infancy and adolescence (Lam 2018, Dabaj
45	2021, Kalfon 2021, Stuut 2021). Most affected individuals require constant daily care due to
46	difficulty performing activities such as feeding, toileting, and bathing, and many are unable to
47	walk or speak (Lam 2018).

48 NGLY1 Deficiency is caused by mutations in the *NGLY1* gene that encodes the cytosolic protein

49 *N*-glycanase 1, or NGLY1 (Enns 2014). NGLY1 cleaves *N*-glycans from proteins targeted for

50 degradation as part of the endoplasmic reticulum-associated degradation (ERAD) pathway.

51 ERAD is a cellular quality control pathway in which misfolded or improperly processed proteins

52 in the endoplasmic reticulum (ER) are translocated to the cytosol and delivered to the

53 proteasome for degradation. NGLY1 cleaves N-linked glycans from ERAD substrate

54 glycoproteins by hydrolyzing the proximal N-acetylglucosamine-asparagine (GlcNAc-Asn)

55 amide bond prior to degradation by the proteasome. This cleavage results in two products, a free 56 oligosaccharide and a deaminated protein (Suzuki 2016). In the absence of NGLY1, glycans can 57 be cleaved from the protein at alternate positions within the glycan, resulting in an incompletely 58 deglycosylated protein that retains the proximal GlcNAc bound to Asn. This protein can then be 59 degraded to peptides, which are hydrolyzed to amino acids. Because the substrate GlcNAc-Asn 60 bond normally cleaved by NGLY1 remains intact, GlcNAc-Asn (GNA) accumulates in the 61 cytosol in cells that lack NGLY1 activity (Haijes 2019; Mueller 2022). As a consequence, GNA 62 levels are consistently elevated in NGLY1 deficient organisms and cells (Mueller 2022) and can 63 be measured using a quantitative assay in dried blood spots, urine, and plasma samples from 64 NGLY1 Deficiency patients (Haijes 2019; Mueller 2022). 65 Restoration of NGLY1 activity in NGLY1 deficient cellular and animal models leads to a 66 reduction of GNA levels. Thus measurement of GNA concentration directly reflects NGLY1 67 activity and could be expected to predict clinically meaningful restoration of NGLY1 activity in 68 a therapeutic setting (Haijes 2019; Mueller 2022; Zhu 2022). A reliable biomarker for NGLY1 69 Deficiency is critical given the small population of affected individuals, the slowly progressive 70 nature of the disease, and the high degree of phenotypic variability (Mueller 2022). 71 The specific factors underlying the heterogenous presentation of NGLY1 Deficiency are not 72 known. Diagnosis of NGLY1 Deficiency is based on a combination of genetic testing, a detailed 73 medical history, and clinical examination to identify key clinical features, particularly 74 (hypo)alacrima, which is only present in very few disorders. Increased levels of plasma or urine 75 GNA may support a diagnosis of NGLY1 Deficiency when genetic testing shows variants of

76 uncertain significance (Haijes 2019; Mueller 2022). Given the rarity of the disease and its

heterogenous nature, there is often a significant delay between onset of symptoms and diagnosis
(Enns 2014, Adams 2018).

There are no approved treatments for NGLY1 Deficiency; rather, symptoms must be managed daily by caretakers. Symptomatic treatments include feeding tubes to provide nutrients; lubricating eye drops or ointments for dry eyes related to poor tear production; anti-seizure medication; occupational, physical, and speech therapy to assist with activities of daily living; and psychosocial support for families and caregivers (Lam 2018; Lam 2017). Nearly half of patients also require invasive procedures or surgery for musculoskeletal issues associated with NGLY1 Deficiency (Cahan 2019).

86 To support the development of disease-modifying therapies, a full elucidation of the natural

87 history and clinical manifestations of NGLY1 Deficiency is needed. As the disorder was

88 recently identified (Need 2012), a prospective natural history study (NHS) that enrolled a

89 substantial portion of the known affected individuals was conducted to improve understanding of

90 the presentation and course of the disorder.

91 This paper reports on the findings of the NGLY1 Deficiency prospective NHS described above

92 (NCT03834987). The objectives of this study were to understand the clinical spectrum and

93 progression of NGLY1 Deficiency using standardized clinical and neurodevelopmental

94 assessments, and to identify and define clinical and biomarker endpoints for use in therapeutic95 trials.

96 Materials and Methods

97 Study design

98	The NGLY1 NHS reported here was a prospective, longitudinal observational study conducted
99	by Stanford University (http://clinicaltrials.gov, NCT03834987) and funded by the Grace
100	Science Foundation (gracescience.org), a research and advocacy group for NGLY1 Deficiency.
101	The planned enrollment was up to 50 patients with a confirmed diagnosis of NGLY1 Deficiency,
102	with up to 15 time points per participant. Study procedures included annual in-person ("onsite"
103	participants) or annual remote ("remote" participants) evaluations along with remote assessments
104	for each group every 4-months between annual evaluations. Established developmental and
105	health-related quality of life (HRQoL) measures as well as standardized laboratory and clinical

107 **Participants** 

assessments were employed.

106

108 Participants included males and females of any age with a suspected or confirmed diagnosis of 109 NGLY1 Deficiency based on the identification of (likely) pathogenic variants in both NGLY1 110 alleles and clinical characteristics consistent with the disease. Parent(s)/legal representative(s) of 111 participants were required to give informed consent/assent for study participation; for the results 112 of the study to be presented at scientific/medical meetings or published in scientific journals; and 113 to be willing for the participant to provide clinical data, provide biological samples, and 114 participate in standardized assessments. Willingness to travel to Palo Alto, CA was favored, but 115 not required. Each study participant's data records were assigned a unique code number. 116 Information about the code was kept in a secure location and access was limited to key research 117 study personnel.

Participants were excluded from the study if they had a second, confirmed disorder affectingneurodevelopment or with overlapping symptoms of NGLY1 Deficiency.

6

120 Participants were permitted to be enrolled as "onsite" or "remote" participants. Onsite

- 121 participants were scheduled to visit the clinical site once per year for the study duration, with 2
- 122 telephone / video visits in between each annual visit at 4-month intervals. Remote participants
- 123 were scheduled for annual telephone / video visit with 2 telephone / video visits in between each
- annual visit at 4-month intervals. Most assessments began at baseline, except for SSDS,
- 125 Schirmer's test, and the question about the most bothersome symptom, which began in Year 2.
- 126 These assessments therefore have a lower number of data points.
- 127 Participants enrolled in the study at different times (between February 15, 2019 and October 14,
- 128 2020); however, the end date of the study was the same for all patients. For this reason, the
- number of participants with an assessment at each study time point was variable and generally
- 130 decreased over time. This effect was compounded by the COVID-19 pandemic, which caused
- 131 delays in enrollment and assessments.

#### 132 Assessments

#### 133 Primary Objectives

There were two primary outcome measures for the NGLY1 Deficiency NHS: 1) developmental assessment at baseline and longitudinally, as measured by the established scales, and 2) disease course over time as measured by standardized medical histories.

- 137 The following established scales were used for the primary outcome capturing development
- 138 assessment: Mullen Scales of Early Learning (MSEL), Vineland Adaptive Behavior Scales, 3<sup>rd</sup>
- 139 Edition (Vineland-3), Peabody Scales of Motor Development (PDMS-2), and Beery-Buktenica
- 140 Test of Visual Motor Integration (Beery VMI).

141	The MSEL is a direct assessment and provides a broad global assessment of development in
142	children from birth to 68 months by examining 5 key subscales: gross motor, fine motor, visual
143	reception, expressive language, and receptive language. The developmental quotient (DQ),
144	which is calculated by averaging the 5 areas of the Mullen scale and dividing the developmental
145	age by the chronological age x 100 (a DQ of 100 corresponds to an exact match between the
146	developmental and chronological age), provides an overall approximation of the affected
147	individual's ability to function (Aylward 2008).
148	The Vineland-3 is a parent/caregiver-reported measure that uses a semi-structured interview to
149	assess adaptive behavior across four domains: Communication, Daily Living Skills,
150	Socialization, and Motor Skills. It is used to support the diagnosis of intellectual and
151	developmental disabilities (Farmer 2020). The Vineland Adaptive Behavior Composite is
152	derived from the Communication, Daily Living Skills, and Socialization domains.
153	The PDMS-2 includes five subscales used to calculate 2 quotients: Grasping and Visual-Motor
154	Integration (which are used to calculate the Fine Motor Quotient [FMQ]); and Stationary,
155	Locomotion and Object Manipulation, replaced by the Reflexes subtest for children up to eleven
156	months old (which are used to calculate the Gross Motor Quotient [GMQ)]). FMQ and GMQ can
157	also be combined to yield a Total Motor Quotient (TMQ). FMQ, GMQ, and TMQ are scored
158	similarly to the DQ. They compare developmental age to chronological age; a score of 100
159	represents an exact match between developmental age and chronological age. Scores that are
160	lower or higher than 100 represent a developmental age that is lower or higher than the
161	chronological age, respectively (Rebelo 2021).

162	The Beery VMI is administered by a clinician and assesses the ability to integrate visual and
163	motor activities in individuals 2 years of age and older. It requires individuals to copy a sequence
164	of geometric forms using paper and pencil. While the Beery VMI was a planned assessment for
165	this NHS, participants in the study were too developmentally impaired to attempt this test
166	(Spencer 2010).
167	The Bruininks-Oseretsky Test of Motor Proficiency Second Edition (BOT-2) and Differential
168	Ability Scales-II (DAS-2) were used for higher functioning subjects but are not discussed in this
169	paper because they were only conducted in 3 participants.
170	The primary outcome measure of disease course over time was measured by collecting
171	standardized medical histories that included general physical evaluations, clinical neurologic
172	evaluations, standardized dysmorphology evaluations, laboratory studies (comprehensive
173	metabolic panel, liver function tests, creatine kinase, lactic acid, fasting lipid panel,
174	adrenocorticotropic hormone [ACTH], cortisol, biochemical studies), scoring of movement
175	disorders (including 10-meter walk test [10-MWT]), and standardized and Schirmer's
176	ophthalmologic evaluations.

Schirmer's test was used to evaluate (hypo)alacrima. This test determines whether the eye
produces sufficient tears by placing calibrated test strips of non-toxic filter paper within the
lower eyelid of each eye for 5 minutes and measuring the distance traveled by the tears on the
test strips (Karampatakis 2010).

181 The sitting and standing abilities were part of the neurologic exam and used to measure gross 182 motor function (Pereira 2016). Minimal support was defined as hands only, and maximal support 183 was the requirement for truncal support. The 10-MWT was used to measure walking speed in

9

meters per second over a short walking distance at an individual's usual walking speed

185 (comfortable speed) and/or walking as quickly as possible (fast speed) (de Baptista 2020). 186 Secondary Objectives 187 Secondary objectives included identification of clinical endpoints or biomarkers for therapeutic 188 trials, and caregiver and participant QoL at baseline and longitudinally. Participant QoL was 189 measured through the Pediatric Quality of Life Inventory (PedsQL) as reported by the caregiver. 190 The PedsQL measures quality of life in children and adolescents; it includes 23 questions in 4 191 domains: physical, emotional, social, and school functioning. Caregiver QoL was measured 192 through self-report using SF-36. The SF-36 measures quality of life in adults, adolescents, and 193 children and includes 36 questions in 8 domains: vitality, physical functioning, bodily pain, 194 general health perceptions, physical role functioning, emotional role functioning, social role 195 functioning, and mental health. Finally, a single question asking caregivers to identify the most 196 bothersome symptom for the participant was included. 197 Other procedures completed at baseline and longitudinally as tolerated included: 198 electroencephalogram (EEG), seizure diary (when applicable for those experiencing active 199 seizures), nerve conduction studies, and quantitative studies of autonomic function (OSART). 200 EEG and seizure diary results are reported in a separate paper (Levy 2022).

201 Biomarker

184

202 The assay for GNA substrate biomarker has been described previously (Mueller 2022). This

203 assay uses liquid chromatography/tandem mass spectrometry (LC/MS/MS) in positive

204 electrospray ionization mode (ESI+) for the quantitation of GNA in human plasma. Test

205	samples, calibration standards, and QC samples were processed by protein precipitation with
206	acetonitrile to enrich the analyte in the matrix samples. Samples were homogenized in
207	phosphate-buffered saline (PBS) and mixed with three volumes of ice cold Internal Standard
208	Solution (acetonitrile containing 60 ng/ml d3-GNA, Omicron Biochemicals, Inc.; catalog
209	number AAG-004, Lot# Q01-N0816). They were then centrifuged at 6100 g for 30 min. An
210	aliquot of each supernatant was transferred to an autosampler plate. The supernatant was
211	separated via HPLC (Shimadzu VP Series 10 System) and analyzed via MS/MS (Applied
212	Biosystems/MDS SciEx API 4000). Detection and accuracy were assessed in surrogate matrices
213	(PBS + bovine serum albumin [BSA], charcoal stripped serum). Each surrogate matrix was
214	spiked with 30 and 300 ng/ml of GNA (Omicron Biochemicals, Inc.; catalog number AAG-003),
215	processed and analyzed to determine recovery and accuracy. The processed samples were
216	analyzed by LC/MS/MS using a HILIC column. GNA was quantified using d3-GNA ( $\beta$ -D-
217	GlcN[2H3]Ac-(1,N)-Asn) as an internal standard (IS). The calibration range was 5 to 2500
218	ng/mL using 20 $\mu$ L of sample. The analyte/IS peak area ratios (y) versus the nominal analyte
219	concentrations (x) of the calibration samples were used to fit a calibration curve by power
220	regression (origin excluded). The analyte concentrations for the calibration standards, quality
221	control samples, and unknown (study) samples were calculated using the established calibration
222	equation.

# 223 Statistical methodology

This NHS was descriptive; thus, data were considered hypothesis-generating and not subjected to power analysis. Demographic data and baseline disease characteristics were summarized for all enrolled participants. Clinical and biological data were summarized over the study period. Data

11

- 227 were presented descriptively, and regression and/or ANOVA analyzes were performed to
- 228 characterize disease course and any associated markers.
- GNA biomarker data was analyzed using R (version 3.5.1 (2018-07-02) -- "Feather Spray")
- 230 Scripts available upon request.

# 231 **Results**

#### 232 Participant Disposition and Demographics

233 The study enrolled 29 participants with a confirmed diagnosis of NGLY1 Deficiency,15 onsite

234 participants and 14 remote participants. The data presented here expand on the baseline

characteristics and on the disposition of those reported by Levy 2022. Three participants died

during the study period (Table 1). All other patients remained in the study throughout its

duration. Participants were followed for a median of 23 months, with a range of 8-32 months.

238 Because participants entered the study at different times, they were followed for varying lengths

of time up to the study end date. Thus, the number of patients at each time point is provided

240 when describing the results.

- The mean age [range] of participants was 9.93 [1-27] years at entry and 7.1 [0-16.1] years at
- diagnosis. The mean weight [range] expressed as Z-score was -2.08 [-0.57 to -3.97], thus
- indicating for all participants body weights below the norm for age.

#### 244 Table 1: Participant Disposition and Demographics

Demographic	
Number of participants – n	29
- Onsite – n (%)	15 (51.7)
- Remote $-n$ (%)	14 (49.3)
Discontinuations during study – n (%)	None

Demographic	
Deaths during study – n (%)	3 (10.3)
Age at death – age range (number)	10-15 years (2); 20-25 years (1)
Age at: mean (SD)[range] – years	
- Study entry	9.93 (6.279)[1-27]
- Diagnosis	7.1 years $(5.45)[0-16.1]$
Gender – n (%)	29 (100%)
- Male	15 (51.7)
- Female	14 (49.3)
Weight as Z-score - n $(\%)$	15 (52%)
Mean (SD) [range]	-2.1 (0.97) [-0.57 to -3.97]

245

# 246 Developmental Assessments

#### 247 Mullen Scales of Early Learning (MSEL)

248 Participants who were given the MSEL had profound global developmental delays, with most

249 developmental quotient (DQ) scores below 20, indicating a developmental age much lower than

the normative score of 100 +/- 15 (Figure 1). No participant showed improvement in DQ over

time. Generally, the DQ scores were slightly declining over time for individual participants.

252 All MSEL subscales were also profoundly impaired and generally without remarkable

253 improvement; age equivalents were lowest in expressive language and highest in visual reception

(data on file).

255

256



#### 258 Figure 1: Scatter Plot of Mullen-DQ vs Chronological Age

Legend: Individual participant DQ scores over time are shown. The normative value is 100 +/- 15. Black symbols
are female and gray symbols are male subjects.

261 Almost all participants had profound global impairment in adaptive functioning at baseline as

262 reflected in the Vineland Adaptive Behavior Composite (ABC) standard score where a value of

263 100 (SD 15) is considered normal (Figure 2). The baseline mean (SD) was 49.43 (22.076) with a

264 range of 23.0-88.0 (n=14). Annual year 2 showed mean (SD) of 40.80 (16.825) with a range of

- 265 23.0-71.0 (n=10), which was indicative of no improvement. Participants showed global
- 266 impairment in all domains of the Vineland Adaptive Behavior Scales (data on file). While there
- 267 were some fluctuations over time, the magnitudes of change were neither statistically significant

268 nor clinically meaningful; participants generally remained severely impaired. Two participants,





#### 271 Figure 2: Vineland ABC

Legend: Individual participant Vineland ABC scores over time are shown. The normative value is 100 +/- 15
(shaded area). Black symbols are female and gray symbols are male subjects.

# 274 *Peabody Developmental Motor Scales – 2<sup>nd</sup> Edition (PDMS-2)*

275 Participants assessed for the Peabody Developmental Motor Scales – 2<sup>nd</sup> Edition (PDMS-2) had

276 clinically significant impairments in all subscales of gross and fine motor function, The PDMS-2

- provides a more detailed analysis of gross and fine motor skills in children from birth to 71
- 278 months of age. All participants who could be assessed with PDMS-2 showed marked impairment

279	in DQ for Gross Motor (Figure 3A) and Fine Motor (Figure 3B) function and had clinically
280	significant impairments in all subscales of gross and fine motor function. For example, Grasping
281	age equivalence was at or below 8 months and Object Manipulation age equivalence was below
282	or at 20 months (data on file), even though chronologic age was as high as 260 months (~21
283	years old). These data illustrate a profound impairment in upper extremity function in study
284	participants. Profound motor impairment was also observed in all other PDMS-2 domains (data
285	on file). While there were small changes over time for many participants, the profound motor
286	impairments were generally stable or worsening over time.



287



289

# 290 Figure 3: PDMS-2 Gross Motor (A) and Fine Motor (B) Function

Legend: Individual participant PDMS-2 Gross Motor (A) and Fine Motor (B) Function scores over time are shown.
 The normative values are 100 +/-15. Black symbols are female and gray symbols are male subjects.

293

# 294 Clinical Disease Course Over Time

# 295 Motor Function Parameters (Sitting and Standing Ability)

296 Motor function was significantly impaired and showed progression over time (Table 2). At

297 baseline, 92.3% of participants were able to sit unaided, but by Year 2 this percentage declined

- to 60.0%. Correspondingly, the proportion of participants requiring support or who were unable
- to sit increased by Year 2. Less than half of participants (38.5%) were able to stand unaided at
- 300 baseline, and the percentage declined further at Year 2 to 26.7%. Additionally, the proportion of

- 301 participants requiring maximal support or unable to stand increased by Year 2. Review of
- 302 individual participant data confirmed that the worsening trends were due to several participants
- 303 whose function declined over time (Figure 4).

# **304 Table 2: Motor Function Parameters**

	Timeframe*			
Parameter	Baseline n/N (%)	First Annual n/N (%)		
Sitting Ability	Sitting Ability			
Sits unaided	12/13 (92.3)	9/15 (60.0)		
Sits with minimal support	0/13 (0.0)	4/15 (26.7)		
Sits with maximal support	0/13 (0.0)	1/15 (6.7)		
Unable to sit	1/13 (7.7)	1/15 (6.7)		
Standing Ability				
Stands unaided	5/13 (38.5)	4/15 (26.7)		
Stands with minimal support	2/13 (15.4)	2/15 (13.3)		
Stands with maximal support	5/13 (38.5)	7/15 (46.7)		
Unable to stand	1/13 (7.7)	2/15 (13.3)		

305

306 307

18



#### 308

#### 309 Figure 4: Motor Function: Standing Ability

310 Legend: Individual participant standing ability over time is shown. Black symbols are female and gray symbols are 311 male subjects.

312

#### 313 **Ophthalmic Evaluations**

- 314 The Schirmer's test was used to evaluate (hypo)alacrima using calibrated filter paper to measure
- 315 tear production. As shown in Figure 5, the mean distance traveled for tears in the Schirmer's test
- 316 was generally below normal (≤10 mm; Karampatakis 2010) and for many participants was near or
- below the threshold considered strongly positive for (hypo)alacrima ( $\leq 5$  mm) (Li 2012).
- 318 Because Schirmer's test was introduced late in the study, many patients had only a single time
- 319 point collected; longitudinal data for those participants tested more than once showed no
- 320 consistent change over time. Results were generally similar between left and right eyes (data on

321 file).



#### 323 Figure 5: Schirmer's Lacrimation Test

 $\begin{array}{ll} 324\\ 325 \end{array} Legend: Results from left eye. Wetting of \leq 5 mm per 5 minutes is considered a strong positive test for (hypo)alacrima (Li et al 2012). Greater than 10 mm is considered normal (gray line). \end{array}$ 

#### **326 Other Endpoints**

322

#### 327 10-Meter Walk Test (10-MWT)

- 328 Only half of participants were able to attempt the 10-MWT twice or more at the comfortable
- 329 speed at baseline, and the majority (84.6%) were not able to attempt the fast speed trial. As there
- 330 were too few participants for the data to be clinically meaningful, the results are not shown here.

#### 331 Nerve Conduction Studies (NCS)

332	Interpretation of motor and sensory conduction studies showed a mixed polyneuropathy for most
333	patients. Nerve conduction velocity of the median nerve for motor and sensory nerves generally
334	showed values below normal values reported in the literature (Ryan 2019). Of the 18 participants
335	with NCS assessment, 8 (44%) had at least one median nerve assessment that was not
336	measurable (data on file).

# 337 Quantitative Measures of Autonomic Function: Quantitative Sudomotor Axon Reflex Test 338 (QSART)

339 The Quantitative Sudomotor Axon Reflex Test (QSART) measures postganglionic sympathetic 340 sudomotor sweat response. Decreased sweat volume and increased latency (time to onset of 341 sweating) is indicative of peripheral autonomic neuropathy. Participants showed a decreased 342 sweat response (Table 3), with forearm latency and volume shown as a representative location. 343 Mean sweat latency in the forearm was in the high normal to elevated range, indicating delayed 344 sweating (normal values for sweat latency are 60-120 seconds; Illigens 2009). Mean sweat 345 volume in the forearm was in the low normal range at baseline and worsened to below normal at 346 Year 2 (normal values for sweat volume are 0.38-2.86 µL in men and 0.10-1.99 µL in women; 347 Novak, 2011). Other body locations showed generally similar findings (data on file).

#### 348 Table 3: Summary Statistics of QSART

QSART Domain		Timeframe*	
	Baseline Year 1	Annual Year 2	
Forearm Latency (sec)			
n	10	5	
Mean (SD)	109.0 (52.05)	173.0 (81.00)	
Median	100.5	173.0	
Min, Max	20, 177	68, 290	
Forearm Sweat Volume (µL)			
n	10	5	
Mean (SD)	0.5364 (0.45795)	0.0801 (0.05811)	
Median	0.4363	0.0490	
Min, Max	0.047, 1.638	0.042, 0.179	

349

# 350 Quality of Life

351 Caregiver self-reports for the caregiver's QoL per SF-36 did not show change over time (data on352 file).

#### 353 Pediatric Quality of Life Inventory (PedsQL)

- 354 The Pediatric Quality of Life Inventory (PedsQL) is a measure of pediatric HRQoL (Hullmann
- 355 2011). Total scores for participants at baseline (Figure 6) ranged from 33.7 to 95.7, with a mean
- of 50.5, which is lower than total scores for normal development (mean 82.5 to 95.2, depending
- 357 on gender and age group; Valier 2017). Scores by domain were lowest for the Physical domain,
- 358 with a mean (SD) score of 32.57 (24.924) and highest for the Emotional domain, with a mean
- 359 (SD) score of 68.75 (20.283) (data on file). The PedsQL total score (Figure 6) and subdomain
- 360 scores remained generally stable over time (data on file).



361

#### 362 Figure 6: PedsQL (Total Score) vs. Visit

363 Legend: Black symbols are female and gray symbols are male subjects.

364

#### 365 Most Bothersome Symptom

366 When asked to describe the most bothersome symptom of NGLY1 Deficiency, caregivers

367 identified trouble with language/communication (for 13 patients), followed by gross or fine

368 motor deficits, including limited functional hand use (for caregivers of 11 patients) (data on file).

369 GNA levels

- 370 GNA levels were elevated in the plasma of all participants, did not correlate with age, and
- 371 showed minimal change over time (Figure 7). There was no significant linear relationship
- 372 between age and GNA levels, as indicated by the horizontal black line, suggesting GNA levels

- 373 (GNA concentration in plasma) remain consistent over time. For onsite participants, mean (SD)
- 374 GNA plasma concentration was 115 (28.4) ng/mL with range of 57.8 189.0 ng/mL, which was
- 375 4.3-fold over related controls (unaffected siblings and parents) and 8.5-fold over unrelated
- unaffected controls (Mueller 2022). Longitudinal GNA samples (n=10) showed  $\leq$  37 ng/mL
- 377 change over 2-3 years (max min concentration; mean change 23.0 ng/mL +/- 10.8 ng/mL).



378

# Figure 7: Plasma GNA Concentration vs. Age at Collection for Participants as Measured over Time

- 381
   382
   383
   383
   384
   385
   385
   386
   386
   387
   388
   388
   388
   388
   389
   389
   380
   380
   380
   381
   381
   381
   381
   382
   383
   384
   384
   385
   385
   386
   386
   387
   388
   388
   388
   388
   388
   388
   388
   389
   389
   380
   380
   380
   381
   381
   381
   381
   382
   383
   384
   384
   385
   385
   386
   386
   387
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
   388
- relationship. The line is the trend line with statistical correlation shown. Each red point represents a measurement, and red points with short black lines between them are measurements for the same participant.

#### 385 Laboratory Studies

386 Laboratory study results were generally unremarkable, except for ALT (Figure 8) and AST 387 (Figure 9) levels, which were elevated in some participants. Those with elevated ALT/AST 388 values showed improvement over time, especially among the younger patients. The liver 389 transaminases were not associated with elevated total bilirubin levels and did not reach levels 390 indicative of severe liver disease.



391

#### 392 Figure 8: ALT (U/L) vs Chronological Age

393 Legend: If participants had multiple lab measurements at the same visit, the highest value was selected for analysis.



394

#### **395** Figure 9: AST (U/L) vs Chronological Age

396 Legend: If participants had multiple lab measurements at the same visit, the highest value was selected for analysis.

# 397 **Discussion**

398 This prospective NHS was undertaken to characterize the clinical characteristics, disease course, 399 and potential clinical trial endpoints for NGLY1 Deficiency, a severely debilitating, ultra-rare, 400 autosomal recessive, neurodevelopmental disorder. Consistent with previous publications, the 401 core features of the disease, global developmental delay and/or intellectual disability, a 402 hyperkinetic movement disorder, transient elevation of transaminases, and (hypo)alacrima 403 (Adams 2018; Enns 2014; Lam 2018; Levy 2022) were found to be profound and did not show 404 spontaneous improvements, as with typical childhood development over time. The natural 405 history was generally slowly progressive or at best stable over at least a 1-year period. This 406 publication reports on neurodevelopmental outcomes, disease course over time, laboratory 407 studies, HRQoL and biomarkers. Mortality is also reported, pointing to the urgency for

408	development of treatments for this devastating disease. This report complements findings on
409	seizures and EEG results previously reported from this NHS (Levy 2022).

410 All participants in this NHS had profound neurodevelopmental impairment as demonstrated by 411 developmental and adaptive skills assessments using standard validated instruments, the MSEL 412 and Vineland 3. Profound impairment was observed in the composite score and in all domains, 413 encompassing expressive and receptive language as well as coping skills and interpersonal 414 relationships. There was a trend in neurodevelopmental outcomes, such that those participants 415 with epilepsy (>50% of participants) had more severe developmental delay (Levy 2022). While 416 there were minor fluctuations over time with the neurocognitive instruments (MSEL and 417 Vineland 3) across all domains assessed, these were not clinically significant and were generally 418 within the expected variability of measurement. There was no evidence of spontaneous 419 improvements and the participants failed to recover functional abilities typical for their 420 chronological age. Rather, individuals with NGLY1 Deficiency either slowly deteriorated further 421 or remained at a level of profound impairment. In clinical trials of potential therapies for NGLY1 422 Deficiency, improvements in neurocognitive assessments could signify treatment efficacy; 423 however, even a stabilization or halting of decline based on these assessments could be 424 considered a beneficial effect of treatment.

Nearly all participants exhibited failure to thrive, manifesting as low weight for age, and motor impairments consisting of delayed/absent attainment of motor milestones as shown on physical exam, PDMS-2, and motor subdomains of the MSEL and Vineland-3. Both gross and fine motor skills were severely impaired. Worsening of already poor gross motor function over time was indicated by the reduction in the proportion of participants who achieved unaided sitting or standing with concurrent increased proportions of participants who could not sit or stand. There

431 were no spontaneous improvements in the ability to sit or stand even though participants were at 432 or older than the ages where these gross motor milestones are expected to be achieved. The 433 ability to sit and stand independently would be expected to greatly impact a patient's and their 434 caregiver's quality of life. Overall, multiple assessment methods pointed toward slowly 435 progressive declines in motor abilities required for self-care and activities of daily living. The 436 motor function results of this NHS suggest that if motor abilities are used as an endpoint in 437 future therapeutic trials, any improvements seen are more likely to be due to the efficacy of the 438 therapy rather than natural improvement with age, and that even a small improvement would be 439 clinically important, given the profound impairment that begins early in life and may worsen 440 over time.

441 Schirmer's test for lacrimation (tear formation) and QSART assessments (sweat response) also 442 indicated impaired functions in participants. These assessments are indicative of autonomic 443 dysfunction in NGLY1 Deficiency (Lam 2018; Pinto 2020; Willems 2022) and were generally 444 stable or worsened over time. Insufficient tear production has an important impact on health in 445 individuals with NGLY1 Deficiency and is associated with corneal damage, including 446 neovascularization, pannus formation, and scarring (Lam 2018). Reduced sweat response 447 (hypohydrosis) requires protective measures against situations that could cause dangerous core 448 body hyperthermia (Lam 2017), such as cooling vests and adequate access to water and air 449 conditioning (Lam 2018).

The majority of participants had impaired HRQoL as measured by PedsQL that showed no clear change over time by total score or by subdomain. Symptoms that were most troublesome to caregivers included difficulties with language/communication and motor deficits (particularly limited functional hand use). The caregivers' impressions are consistent with the deficits seen on the MSEL, which showed profound impairment in language and communication, the Vineland-3,
which showed extensive impairment in gross and fine motor skills, and the PDMS-2, which
showed clinically important impairment in all measures of gross and fine motor skills including
grasp and object manipulation. Caregiver-reported improvement in the symptoms that most
directly affect the HRQoL of participants and their families could represent meaningful
secondary endpoints.

460 GNA has been identified as a substrate biomarker for NGLY1 Deficiency (Mueller 2022).

461 Unlike other potential biomarkers for NGLY1 Deficiency (Lam 2017; Hall 2018; Chang 2019),

462 GNA is a substrate biomarker that directly results from the lack of NGLY1 function. consistently

463 differentiates those individuals affected by NGLY1 Deficiency from those without NGLY1

464 Deficiency (Mueller 2022). Individuals with the inherited metabolic disease

465 aspartylglucosaminuria (AGU) also show elevated GNA levels but can be distinguished from

466 those with NGLY1 Deficiency through genetic testing and consideration of key clinical features.

467 The data presented in this report demonstrate that GNA was elevated in all NHS participants and

468 remained stable over time. In a rat model of NGLY1 Deficiency, virally-mediated delivery of a

469 functional human copy of the NGLY1 gene led to a reduction in GNA levels that correlated with

470 improvement of behavior and locomotor phenotypes (Mueller 2022, Zhu 2022). A similar

471 restoration of NGLY1 function as assessed by normalization of GNA levels might be used as a

472 key endpoint to measure treatment effect and be expected to predict clinical benefit in future

473 NGLY1 gene therapy clinical trials.

474 Liver transaminases were mildly elevated at baseline and stable or, in the case of some younger

475 patients, improved over time. This is consistent with previous reports of NGLY1 Deficiency in

476 which liver dysfunction has been identified as an important phenotype of the disease (Need

2012; Heeley 2015; Lipinski 2020; Rios-Flores 2020; Lipari 2020). Although AST/ALT levels
were not high enough to be indicative of severe liver disease in this NHS, they should be
followed over time during future interventional studies as part of safety monitoring and,
concurrently, may be an important clinical measure to evaluate for treatment efficacy (Pandey
2022).

482 The current study has some limitations. Because patients entered the study at different times,

483 they had different durations of follow-up data. Year 3 study data were only available for a small

484 subset of patients, thus limiting statistical analyses and conclusions about long-term disease

485 progression. The COVID-19 pandemic delayed or precluded some on-site study visits, which

486 impacted the availability of some data. In addition, patients were not able to perform all of the

487 planned assessments, such as the Beery-Buktenica Test of Visual Motor Integration and the 10-

488 MWT, due to the profound neurological and physical impairments associated with NGLY1

489 Deficiency.

490 The data presented here provide valuable insights about the clinical course of NGLY1

491 Deficiency. The sample size of 29 participants in this NHS represents a substantial proportion of

the population of approximately 100 identified individuals with NGLY1 Deficiency (Enns 2014;

493 Pandey 2022; data on file). This study demonstrates that the profound neurodevelopmental

494 impairments, quality of life, and other outcomes of NGLY1 Deficiency do not improve and often

495 decline over at least a one-year period, despite existing interventions like physical therapy and

496 symptom management. This dataset informs endpoints, selection of assessment tools, and

497 monitoring intervals for interventional clinical trials. Such assessments include GNA levels as a

498 pharmacodynamic biomarker, instruments that measure language/communication and motor

499 deficits (particularly improved hand use), HRQoL, clinical/caregiver global impressions of

500 change, tear production, and QSART. Seizures and neurophysiologic characterization are also

- 501 relevant because, as previously described, almost all participants had EEG abnormalities,
- 502 indicating increased risk of epilepsy (Levy 2022). As the overall disease course shows a slow but
- 503 progressive decline in neurocognitive and motor function, interventions that result in
- 504 stabilization or a slowing of the decline in function could be considered as efficacious.

# 505 **Declaration of interest**

- 506 Authors S.S.D., S.T., W.F.M., B.J.B., and M.W. are employees of Grace Science, LLC. K.J.L. is
- 507 a consultant for Grace Science Foundation.

# 508 Acknowledgements

- 509 Funding for this study was provided by a grant from Grace Science Foundation (GSF) to
- 510 Stanford University. Dr Maura Ruzhnikov contributed to protocol development and was the
- 511 principal investigator of the study. Dr Stephen Maricich reviewed and analyzed preliminary data.
- 512 Medical writing, editing, and design assistance was provided by Judy Wiles, Trish Rawn, and
- 513 Selma Tse of Facet Communications Inc. Caroline Stanclift served as a liaison between GSF and

514 the trial site; graphic presentations were provided by Alicia Newton.

# 515 Author contributions

- 516 Conceptualization: S.S.D., W.F.M., B.J.B., M.W., K.J.L., J.K.; Study coordination: M.W.,
- 517 C.H.F; Data curation: S.S.D., W.F.M.; Formal analysis: S.T., P.V., S.S.D., W.F.M., C.H.F., S.M;
- 518 Investigation: S.D.D., W.R.M., J.K., J.P., C.H.F, S.M.; Visualization: S.T., W.F.M., K.J.L.;

- 519 Writing-original draft: S.T., P.V., S.S.D., W.F.M; Writing-review & editing: S.T., P.V., S.S.D.,
- 520 W.F.M., B.J.B., M.W., K.J.L, J.K., J.P., C.H.F.

# 521 Data and code availability

- 522 The datasets that support this study are available from the corresponding author upon reasonable
- 523 request, subject to institution ethical considerations for participant privacy and consent.

#### 524 Ethical Approval

525

526 Informed consent was obtained from all study participants according to the study protocol

- 527 approved by the Stanford Institutional Review Board (IRB Protocol # 47335). Parents gave
- 528 written informed consent for their children or dependents.

# 529 **References**

- Adams, J., and Schaaf, C.P. (2018) Diagnosis and genetics of alacrima. Clin. Genet. 94, 54–60
- 531 Aylward, G.P., Jeffries, L.M., et al. (2008) Mullen Scales of Early Learning. Developmental-
- 532 Behavioral Pediatrics, *Ch* 7, 123-201.
- 533 Cahan, E. M., Frick, S.L. (2019) Orthopaedic phenotyping of NGLY1 deficiency using an
- international, family-led disease registry. Orphanet J Rare Dis, 14, article number: 148.
- 535 Chang C.A., Wei X.C., Martin S.R., Sinasac D.S., Al-Hertani W. Transiently elevated plasma
- 536 methionine, S-adenosylmethionine and S-adenosylhomocysteine: Unreported laboratory findings
- in a patient with NGLY1 deficiency, a congenital disorder of deglycosylation. JIMD Rep. 2019;
- 538 49:21–29. doi: 10.1002/jmd2.12064.

- 539 Dabaj I, Sudrié-Arnaud B, Lecoquierre F, et al. NGLY1 deficiency: A rare newly described
- 540 condition with a typical presentation. Life. 2021;11:1<u>87. https://doi.org/10.3390/life11030187.</u>
- de Baptista, Cyntia R J A et al. (2020) Methods of 10-Meter Walk Test and Repercussions for
- 542 Reliability Obtained in Typically Developing Children. Rehabilitation research and practice
- 543 *2020 4209812*.
- 544 Enns GM, Shashi V, Bainbridge M, et al. (2014) Mutations in NGLY1 cause an inherited
- 545 disorder of the endoplasmic reticulum-associated degradation pathway. Genet Med. 16(10), 751-
- 546 758.
- 547 Farmer, C., Adedipe, D., Bal, V., et al. (2020) Concordance of the Vineland Adaptive Behaviour
  548 Scales, Second and Third Editions. J Intellect Disabil Res. *64(1)*, 18-26.
- 549 Haijes, H.A., de Sain-van der Velden, M.G.M., Prinsen, H., et al (2019) Aspartylglycosamine is
- a biomarker for NGLY1-CDDG, a congenital disorder of deglycosylation. *Mol. Genet. Metab.*

**127**, 368–372.

- 552 Hall, P.L., Lam, C., Alexander, J.J., Asif, G., Berry, G.T., Ferreira, C., Freeze, H.H., Gahl, W.A.,
- 553 Nickander, K.K., Sharer, J.D., Watson, C.M., Wolfe, L., and Raymond, K.M. (2018) Urine
- oligosaccharide screening by MALDI-TOF for the identification of NGLY1 deficiency. *Mol.*
- 555 *Genet. Metab.* **124**, 82–86.
- 556 Heeley J., Shinawi M. Multi-systemic involvement in NGLY1-related disorder caused by two
- 557 novel mutations. Am. J. Med. Genet. A. 2015;167A:816–820.

- Hullmann SE, Ryan JL, Ramsey RR, et al. Measures of general pediatric quality of life. Arthritis
  Care & Research. 2011; 63(S11):S420-S430.
- 560 Illigens BMW, Gibbons CH. Sweat testing to evaluate autonomic function. Clin Auton Res.

561 2009;19(2):79-87.

562 Kalfon L, Baydany M, Samra , et al. Congenital Hypotonia: Cracking a SAGA of

563 consanguineous kindred harboring four genetic variants. Mol Genet Genomic Med.

564 2022;10:e1849.

565 Karampatakis, V., Karamitsos, A., Skriapa, A., Pastiadis, G. (2010) Comparison between normal

values of 2- and 5-minute Schirmer test without anesthesia. Cornea, 29(5), 497-501.

- 567 Lam C, Ferreira C, Krasnewich D, et al. Prospective phenotyping of NGLY1-CDDG, the first
- 568 congenital disorder of deglycosylation. Genet Med. 2017;19(2):160-168.
- 569 Lam C, Wolfe L, Need A, et al. NGLY1-Related Congenital Disorder of Deglycosylation. Gene
- 570 Reviews. 2018; https://www.ncbi.nlm.nih.gov/sites/books/NBK481554/.
- 571 Levy RJ, et al. Delineating the epilepsy phenotype of NGLY1 deficiency. JIMD. 2022;
- 572 <u>https://doi.org/10.1002/jimd.12494</u>.
- 573 Li N, Deng XG, He MF. Comparison of the Schirmer I test with and without topical anesthesia for
- 574 diagnosing dry eye. Int J Ophthalmol. 2012; 5(4):478-481.
- 575 Lipari Pinto P., Machado C., Janeiro P., Dupont J., Quintas S., Sousa A.B., Gaspar A. NGLY1
- 576 deficiency—A rare congenital disorder of deglycosylation. JIMD Rep. 2020;53:2–9.
- 577 doi: 10.1002/jmd2.12108

- 578 Lipiński P., Cielecka-Kuszyk J., Socha P., Tylki-Szymanska A. Liver involvement in NGLY1
- 579 congenital disorder of deglycosylation. Pol. J. Pathol. 2020;71:66–68.
- 580 doi: 10.5114/pjp.2020.92994.
- 581 Mueller WF, Zhu L, Tan B, et al. GlcNAc-Asn is a biomarker for NGLY1 deficiency. J
- 582 *Biochem*. 2022;171(2):177-186. doi:10.1093/jb/mvab111. Accessed 31 October 2022:
- 583 https://academic.oup.com/jb/article/171/2/177/6410260
- 584 Need A.C., Shashi V., Hitomi Y., Schoch K., Shianna K.V., McDonald M.T., Meisler M.H.,
- 585 Goldstein D.B. Clinical application of exome sequencing in undiagnosed genetic conditions. J.
- 586 Med. Genet. 2012; 49:353–361. doi: 10.1136/jmedgenet-2012-100819.
- 587 Novak P. Quantitative autonomic testing. Journal of Visualized Experiments. 2011. doi:
  588 10.3791/2502
- 589 Pandey A, Adams JM, Han SY. Jafar-Nejad H. NGLY1 Deficiency, a Congenital Disorder of
- 590 Deglycosylation: From Disease Gene Function to Pathophysiology. Cells. 2022;11(7):1155.
- 591 Pereira AC, Ribeiro MC, Araujo APQC. (2016) Timed motor function tests capacity in healthy
- 592 children. Arch Dis Child. **101**;147-151.
- 593 Pinto, P. L., Machado, C., Janiero, P., et al. (2020) NGLY1 deficiency a rare congenital
- 594 disorder of glycosylation. JIMD Rep, 53(1): 2-9.
- 595 RAND Corporation. 36-item short form survey (SF-36): scoring instructions.
- 596 https://www.rand.org/health-care/surveys tools/mos/36-item-short-form/scoring.html. Accessed
- 597 July 12, 2022.

- 598 Rebelo M, Serrano J, Duarte-Mendes P, et al. Evaluation of the Psychometric Properties of the
- 599 Portuguese Peabody Developmental Motor Scales-2 Edition: A Study with Children Aged 12 to
- 600 48 Months. Children (Basel). 2021;8(11):1049.
- 601 Rios-Flores I.M., Bonal-Perez M.A., Castellanos-Gonzalez A., Velez-Gomez E., Bertoli-Avella
- 602 A.M., Bobadilla-Morales L., Pena-Padilla C., Appendini-Andrade V., Corona-Rivera A.,
- 603 Romero-Valenzuela I., et al. Acute liver failure in a male patient with NGLY1-congenital
- disorder of deglycosylation. Eur. J. Med. Genet. 2020;63:103952.
- 605 doi: 10.1016/j.ejmg.2020.103952.
- 606 Ryan, C.S., Conlee, E.M., Sharma, R., et al. Nerve conduction normal values for
- 607 electrodiagnosis in pediatric patients. Muscle Nerve. 2019;60(2):155-160.
- 608 Spencer, T.D., Kruse, L. Beery-Buktenica Developmental Test of Visual Motor Integration.
- 609 (2010) Encyclopedia of Autism Spectrum Disorders. In: Volkmar, F.R. (eds) Encyclopedia of
- 610 Autism Spectrum Disorders. Springer, New York, <u>NY. https://</u>doi.org/10.1007/978-1-4419-
- 611 1698-3\_1886.
- 612 Stuut T, Popescu O, Oviedo A (October 29, 2021) N-Glycanase 1 Deficiency is a rare cause of
- 613 pediatric neurodegeneration with neuronal inclusions and liver steatosis. Cureus 13(10): e19126.
- 614 Suzuki, T., Huang, C., and Fujihira, H. (2016) The cytoplasmic peptide:N-glycanase (NGLY1) –
- 615 structure, expression and cellular functions. *Gene* **577**, 1–7.
- 616 Valier ARS, Bacon CEW, Bay RC, et al. Reference values for the Pediatric Quality of Life Scale
- 617 Inventory and the Multidimentional Fatigue Scale in adolescent athletes by sport and sex. Am J
- 618 Sports Med. 2017;45(12):2723-2729.

- 619 Willems, M., Wells, C. F., Coubes, C., et al. (2022) Hypoalacrima and alacrima as diagnostic
- 620 features for genetic or congenital conditions. Investigative Ophthalmology & Visual Science, 63
- 621 3.
- 622 Zhu L, Tan B, Dwight S, et al. AAV9-NGLY1 gene replacement therapy improves phenotypic
- and biomarker endpoints in a rat model of NGLY1 Deficiency. Meth Clinical Dev., 2022;27:269-
- 624 271. doi:https://doi.org/10.1016/j.omtm.2022.09.015:
- 625 <u>https://www.sciencedirect.com/science/article/pii/S2329050122001401</u>